Shares of Bio-Techne Corp. advanced 5.19% to $57.60 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.77% to 6,890.07 and the ...

Bio-Techne Corporation (NASDAQ:TECH) is one of the 10 best life sciences stocks to buy according to hedge funds. On February 5, Daniel Arias from Stifel Nicolaus reaffirmed his Hold rating on ...

Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity ...

MINNEAPOLIS, Feb. 2, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the launch of Cultrex™ ...

Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

Bio-Techne's Ella platform achieves CE-IVD marking expanding access to rapid, cartridge-based immunoassays for European clinical labs: Minneapolis Tuesday, February 17, 2026, 14:0 ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...